Fate Therapeutics Reports First Quarter 2020 Financial Results and Highlights Operational Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- US stock futures rise as oil pullback amplifies Fed rate-hike boost
- Oil prices extend losses as supply disruption fears ease
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Trade the FOMC: How stocks tend to perform on Fed hike days
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
Fate Therapeutics (FATE) Misses Q1 EPS by 5c
May 11, 2020 5:12 PM EDTFate Therapeutics (NASDAQ: FATE) reported Q1 EPS of ($0.44), $0.05 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $2.52 million versus the consensus estimate of $1.8 million.
We are encouraged by the resilience of our employees, our clinical trial investigators and participating patients,... More
